Stephen Shuttleworth

Title: The Innovative Contributions of Stephen Shuttleworth

Introduction

Stephen Shuttleworth is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target lipid kinases. With a total of 5 patents to his name, Shuttleworth's work has implications for treating serious disorders, including cancer.

Latest Patents

Shuttleworth's latest patents focus on pharmaceutical compounds that are designed to inhibit lipid kinases, such as PI3K. One of his notable inventions includes compounds of Formulae Ia, which are useful for treating disorders mediated by lipid kinases. These compounds can be utilized for in vitro, in situ, and in vivo diagnosis, prevention, or treatment of related disorders in mammalian cells. Another significant patent involves a pharmaceutical composition that includes the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate, which serves as an active ingredient in therapeutic applications.

Career Highlights

Throughout his career, Stephen Shuttleworth has worked with prominent companies in the pharmaceutical industry, including F. Hoffmann-La Roche AG and Genentech, Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of medicinal chemistry.

Collaborations

Shuttleworth has collaborated with several professionals in his field, including Adrian Folkes and Tim Hancox. These partnerships have facilitated the advancement of innovative solutions in pharmaceutical research.

Conclusion

Stephen Shuttleworth's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of serious health conditions.